Regional Consultation on access to Direct-Acting Agents for hepatitis C treatment

With this consultation convened by TREATASIA, we hope that we will be able to clearly understand the anti-diversion measures that have been promoted by pharmaceutical companies to prevent the resale of anti-hepatitis C drugs and strategic ways to respond to these measures and increase community awareness of their potential negative impact on treatment access and implications for patients’ rights. We also hope we will have the opportunity to understand how the voluntary licenses are being implemented for Sofosbuvir, the recent rejection of a related patent application in India and consequent appeals, timelines for initiation and scale-up of generic production, and pricing negotiations within the region.


TREAT Asia Fact Sheet

This fact sheet summarizes the major recommendations of WHO first guidelines on screening, care, and treatment of hepatitis C infection.